Mirum Pharmaceuticals, Inc. announced a private placement financing agreement with TCGx for 1,000,000 shares of its Common Stock.
The private placement is priced at $68.48 per share, resulting in approximately $68.5 million in gross proceeds.
The financing, combined with a previous $200 million private placement, aims to support clinical development and commercial activities post the acquisition of Bluejay Therapeutics.
Private Placement Agreement
Mirum Pharmaceuticals secured a private placement financing deal with TCGx for 1,000,000 shares of Common Stock at $68.48 per share.
Funding Purpose
The funds from this financing, along with a prior $200 million private placement, will be utilized for clinical development and commercial activities post the Bluejay Therapeutics acquisition.
Concurrent Closures
The private placements are expected to close simultaneously with the proposed acquisition of Bluejay Therapeutics in the first quarter of 2026, subject to regulatory approvals and standard closing conditions.
- The additional private placement financing underscores Mirum Pharmaceuticals' commitment to securing funding for its strategic goals, particularly in the realm of clinical development and commercial operations.
- The influx of funds from the private placements aligns with Mirum's growth trajectory, especially following the anticipated acquisition of Bluejay Therapeutics, showcasing a bolstered financial position for the company.
Mirum Pharmaceuticals' recent private placement financing with TCGx represents a significant milestone in bolstering its financial resources to further its clinical development efforts and commercial endeavors, setting a strong foundation for future growth and expansion.